STOCK TITAN
  1. Home
  2. Sec-filings
  3. ENTX
  4. [8-K] Entera Bio Ltd. Reports Material Event

[8-K] Entera Bio Ltd. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ENTX logo
Entera Bio Ltd

NASDAQ:ENTX

ENTX Rankings

#4770 Ranked by Market Cap
N/A Ranked by Dividends

ENTX Latest News

Aug 28, 2025
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
Aug 8, 2025
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
Jul 28, 2025
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Jul 8, 2025
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Jun 26, 2025
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting

ENTX Latest SEC Filings

Aug 8, 2025
[8-K] Entera Bio Ltd. Reports Material Event
Aug 8, 2025
[10-Q] Entera Bio Ltd. Quarterly Earnings Report
Jul 28, 2025
[8-K] Entera Bio Ltd. Reports Material Event
Jul 18, 2025
[Form 4] Entera Bio Ltd. Insider Trading Activity
Jul 18, 2025
[Form 4] Entera Bio Ltd. Insider Trading Activity

ENTX Stock Data

98.63M
34.56M
24.31%
22.36%
0.12%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Israel
JERUSALEM